https://www.has-sante.fr/jcms/p_3470178/fr/acces-precoce-des-medicaments-un-bilan-positif-apres-deux-ans-de-mise-en-place-du-dispositif 2023 France technical report devices GNAQ Gene Mutation MGMT Gene Promoter Methylation Positive Lymph Node ATRX Gene Mutation During or After PAS Positive GDC Therapeutic Agent Terminology BAP1 Gene Mutation NRAS Gene Mutation pharmaceutical preparations Status Post ETV Gene Rearrangement Hepatitis C Virus RNA Positive GNA11 Gene Mutation Entrapment of Device SDHA Positive HRAS Gene Mutation ESR2 Positive device, nos ERBB2 Gene Amplification TERT Promoter Mutation PAX8 Gene Rearrangement One to Two Years SDHB Positive ERBB2 Gene Mutation Positive Number Checkup RET/PTC Rearrangement Progesterone Receptor Positive ERG Gene Rearrangement FGFR3 Gene Mutation FGFR2 Gene Mutation Set, Psychology KIT Positive FGFR1 Gene Rearrangement drug, nos Hepatitis B Surface Antibody Positive CDH1 Gene Mutation Balance Sheet equipment and supplies 1p/19q Codeletion Hepatitis B DNA Positive Estrogen Receptor Positive ANO1 Positive c-MET Gene Amplification Positive EBV Test FGFR3 Gene Rearrangement FGFR2 Gene Rearrangement IDH Gene Family Mutation Hepatitis B Virus Surface Antigen Positive PD-L1 Positive Human Immunodeficiency Virus Positive Pharmacologic Substance CTNNB1 Gene Mutation KRAS Gene Mutation
--- https://pepite-depot.univ-lille.fr/RESTREINT/Th_Medecine/2023/2023ULILM132.pdf 2023 France dissertations, academic Additional Surgery for New Tumor Event Present Adjuvant Post-operative Immunological Therapy Was Administered KIT Mutation Analysis Was Performed Any Metastatic Diagnosis Present NF1 Mutation Analysis Was Performed Cancer History Present IDH Gene Family Mutation Adjuvant Post-operative Radiation Therapy Was Administered Adjuvant Post-operative Targeted Molecular Therapy Was Administered Chief Complaint Caused by Trauma Adjuvant Post-operative Chemotherapy Was Administered ATRX Gene Mutation Interferon Gamma Treatment was Administered Prior to Specimen Resection Patient was Previously Evaluated for Current Chief Complaint Minor Criteria for Rheumatic Heart Disease Present Adjuvant I-131 Therapy Positive Use of Smokeless Tobacco at Time of Diagnosis Positive Intervention Given for Kawasaki Disease Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event Documentation Present History of Colorectal Cancer Positive Has Sibling Adjuvant Post-operative Pharmaceutical Therapy Was Administered Family History of Stomach Cancer Present Interferon Gamma Treatment was Administered 90 Days Prior to Specimen Resection EGFR Mutation Analysis Was Performed Intercurrent Illness is Present at Onset of Chief Complaint Preoperative IV Opiates were Administered ROS1 Rearrangement Analysis Was Performed Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event Has Response to Intervention for Kawasaki Disease First Degree Family History of Primary Brain Tumor Positive Radiation Was Administered as an Additional Treatment for a New Tumor Event Medication Taken Trial Phase spirituality KRAS Mutation Analysis Was Performed Known History of Congenital Heart Disease Hypertension Present Tumor Progression Present After Initial Treatment Lymph Node Dissection Was Performed Therapeutic Ionizing Radiation to Head History Present Peripheral Blood Immunophenotyping and Cytochemistry Were Performed First Degree Family History Thyroid Cancer Positive Lost To Follow-Up Speak EGFR Gene Amplification PTEN Gene Mutation IDH Family Mutation Analysis Was Performed Radiation History Positive Preoperative IV Sedation was Administered Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed RET Rearrangement Analysis Was Performed Preoperative IV Antacids were Administered MET Mutation Analysis Was Performed New Disease is Multifocal Chemotherapy Received ERBB2 Mutation Analysis Was Performed History of Medical Treatment Present Multiple Known Primary Tumors Present at Initial Melanoma Diagnosis Patient was Postmenopausal with no Prior Oophorectomy PDGFRA Mutation Analysis Was Performed First Degree Family History Cancer Positive Additional Surgery for New Loco-Regional Tumor Event Was Performed Known History of Gestational Complication Fluorescence In Situ Hybridization Was Performed 10q23/PTEN Locus Deletion Analysis Was Performed Additional Molecular Studies Were Performed Another Form of Birth Control was Used EGFR Amplification Analysis Was Performed Known History of Rheumatic Fever Other Preoperative IV Medications were Administered Physician Diagnosed Diabetes Present Routine Cytogenetics Were Completed ALK Rearrangement Analysis Was Performed NRAS Mutation Analysis Was Performed Tumor Reoccurrence Present After Initial Treatment Evidence of Disease Present after Completion of Therapy Chemical/Occupational Exposure Present BRAF Rearrangement Analysis Was Performed Regular Smokeless Tobacco Use for Six Weeks or More Positive Preoperative IV Antiemetics were Administered Additional Surgery for New Metastatic Tumor Event Was Performed BRAF Mutation Analysis Was Performed Regional Anesthesia was Administered 1p/19q Deletion Analysis Was Performed What Month is it IV Anesthesia was Administered YES1 wt Allele Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor
Event ATRX Mutation Analysis Was Performed Known History of Illicit Drug Use New Tumor Event After Initial Treatment Present SDH Complex Mutation Analysis Was Performed Known History of Kawasaki Disease PTEN Mutation Analysis Was Performed TP53 Mutation Analysis Was Performed Subsequent Known Primary Melanoma(s) Found During the Follow-Up Known History of Neonatal Complication Local Anesthesia Agents were Administered Additional Immunohistochemistry Was Performed Participant Exposed to Secondhand Smoke Known History of Alcohol Use MGMT Promoter Methylation Testing Was Performed
--- https://pgtmsite.files.wordpress.com/2024/01/pertuzumab_position-preliminaire_final.pdf 2014 Canada drug information PAX8 Gene Rearrangement KIT Positive pertuzumab NRAS Gene Mutation SDHB Positive c-MET Gene Amplification KRAS Gene Mutation IDH Gene Family Mutation Hepatitis C Virus RNA Positive PAS Positive FGFR2 Gene Rearrangement Positive Number Estrogen Receptor Positive ANO1 Positive breast cancer GNAQ Gene Mutation FGFR1 Gene Rearrangement pertuzumab Human Immunodeficiency Virus Positive 1p/19q Codeletion HER-2 positive breast cancer ESR2 Positive Hepatitis B Virus Surface Antigen Positive HRAS Gene Mutation Breast Cancer Therapeutic Procedure Herero Language Positive Lymph Node Positive EBV Test RET/PTC Rearrangement FGFR3 Gene Mutation SDHA Positive TERT Promoter Mutation Pertuzumab MGMT Gene Promoter Methylation ERG Gene Rearrangement GNA11 Gene Mutation Metastatic Malignant Neoplasm in the Breast breast neoplasms pertuzumab ATRX Gene Mutation ERBB2 Gene Mutation neoplasm, malignant Hepatitis B DNA Positive Hepatitis B Surface Antibody Positive FGFR3 Gene Rearrangement BAP1 Gene Mutation FGFR2 Gene Mutation PD-L1 Positive ERBB2 Gene Amplification CDH1 Gene Mutation CTNNB1 Gene Mutation ETV Gene Rearrangement Progesterone Receptor Positive